Absorption, Distribution, Excretion, Metabolism
Conditions
Keywords
Healthy Volunteer
Brief summary
The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of AZD7325 after intravenous and 14C labeled oral dose
Interventions
DRUGAZD7325
IV Dose
Sponsors
AstraZeneca
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
35 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy subjects Day 1 * Body Mass Index (BMI) \> 18 and \< 30kg/m2
Exclusion criteria
* Clinically relevant disease and abnormalities (past or present) which in the opinion of the investigator, may either put the subject at risk to participate in this study or may influence the results of the study or the subject's ability to participate in the study * Use of prescription medication within 14 days of the first dose of the investigational product * Blood loss in excess of 200 mL within 30 days of Day-1 in excess of 500 mL within 90 days of Day-1 or in excess of 1350 mL within 1 year of Day-1 or donation of blood products within 14 days of Day -1
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess absorption, distribution, metabolism and excretion of AZD7325 after IV dose and 14C oral dose administration | Daily |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate safety and tolerability after a single oral administration of [14C] AZD7325 and after a single intravenous administration of non radio-labelled AZD7325 | Daily |
Countries
United Kingdom
Outcome results
None listed